Rituximab in immunologic glomerular diseases
نویسندگان
چکیده
منابع مشابه
Rituximab in anti-glomerular basement membrane disease.
The role of rituximab has expanded beyond the treatment of non-Hodgkins lymphoma, to include successful management of rheumatoid arthritis, systemic lupus erythematosus, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis and primary glomerulonephritis. Decrease incidence of side-effects or toxicity, coupled with clinical effectiveness, suggests that B-cell depleting agents may ...
متن کاملRituximab in autoimmune diseases.
Rituximab is a monoclonal antibody that depletes B cells from the circulation. It was originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Rituximab was found to be effective in randomised controlled trials for rheumatoid arthritis, granulomatosis with polyangiitis and other antineutrophil cytoplasmic antibody-associated vasculitides. However, evi...
متن کاملRituximab in rheumatic diseases.
Although B cells and T cells are indistinguishable from each other on a blood smear, their phenotypes are clearly different. Differences in membrane immunoglobulin expression were noted in early studies. Subsequently, the development of monoclonal antibodies led to the identification of cluster of differentiation (CD) molecules at the cell surface. The CD pattern can be used to characterize the...
متن کاملHeparanase in glomerular diseases.
Heparanase is an endo-beta(1-4)-D-glucuronidase that degrades heparan sulfate (HS) polysaccharide side chains. The role of heparanase in metastasis, angiogenesis, and inflammation has been established. Recent data suggest a role for heparanase in several proteinuric diseases and an increased glomerular heparanase expression is associated with loss of HS in the glomerular basement membrane (GBM)...
متن کاملRituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
Rituximab is a monoclonal antibody to the CD20 antigen on B-cells that was initially designed and approved for the treatment of non-Hodgkin's B-cell lymphoma in 1997. In the last 15years, it has emerged as a potent immunosuppressant for many immune-mediated diseases, beginning initially with rheumatoid arthritis, and now extending into several other fields, including clinical nephrology. Based ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: mAbs
سال: 2012
ISSN: 1942-0862,1942-0870
DOI: 10.4161/mabs.4.2.19286